• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Amryt Pharma plc (Amendment)

    2/13/23 10:24:07 AM ET
    $AMYT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AMYT alert in real time by email
    SC 13G/A 1 amryt13ga.htm

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934
    (Amendment No. 3)*

     

     

    Amryt Pharma plc

    (Name of Issuer)

     

     

    Ordinary Shares, nominal value £0.06 per share

    (Title of Class of Securities)

     

     

    03217L1061

    (CUSIP Number)

     

     

    December 31, 2022

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    [X]       Rule 13d-1(b)

     

    [X]       Rule 13d-1(c)

     

    [ ]       Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

     

    1 This is the CUSIP number for the Issuer’s American Depositary Shares.

     1 
    CUSIP No. 03217L106

     

    1.Names of Reporting Persons.

    Stonepine Capital Management, LLC

     

    2.Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) ______

    (b) X

     

    3. SEC Use Only

     

    4.Citizenship or Place of Organization California

     

    Number of

    Shares

    Beneficially

    Owned by

    Each Reporting

    Person With:

    5. Sole Voting Power 31,666,1952

     

    6. Shared Voting Power 0

     

    7. Sole Dispositive Power 31,666,1952
    8. Shared Dispositive Power 0

     

    9.Aggregate Amount Beneficially Owned by Each Reporting Person 31,666,1952

     

    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See
    Instructions) ______

     

    11.Percent of Class Represented by Amount in Row (9) 9.9%

     

    12.Type of Reporting Person (See Instructions) IA, OO

     

    2 Represents 6,333,239 American Depositary Shares, each of which represents 5 Ordinary Shares of the Issuer.

     

    1.Names of Reporting Persons.

    Stonepine Capital, L.P.

     

    2.Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) ______

    (b) X

     

    3. SEC Use Only

     

    4.Citizenship or Place of Organization Delaware

     

    Number of

    Shares

    Beneficially

    Owned by

    Each Reporting

    Person With:

    5. Sole Voting Power 31,666,1952

     

    6. Shared Voting Power 0

     

    7. Sole Dispositive Power 31,666,1952
    8. Shared Dispositive Power 0

     

    9.Aggregate Amount Beneficially Owned by Each Reporting Person 31,666,1952

     

    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See
    Instructions) ______

     

    11.Percent of Class Represented by Amount in Row (9) 9.9%

     

    12.Type of Reporting Person (See Instructions) PN

     

    2 Represents 6,333,239 American Depositary Shares, each of which represents 5 Ordinary Shares of the Issuer.

     2 
    CUSIP No. 03217L106

     

    1.Names of Reporting Persons.

    Jon M. Plexico

     

    2.Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) ______

    (b) X

     

    3. SEC Use Only

     

    4.Citizenship or Place of Organization U.S.A.

     

    Number of

    Shares

    Beneficially

    Owned by

    Each Reporting

    Person With:

    5. Sole Voting Power 31,666,1952

     

    6. Shared Voting Power 0

     

    7. Sole Dispositive Power 31,666,1952
    8. Shared Dispositive Power 0

     

    9.Aggregate Amount Beneficially Owned by Each Reporting Person 31,666,1952

     

    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See
    Instructions) ______

     

    11.Percent of Class Represented by Amount in Row (9) 9.9%

     

    12.Type of Reporting Person (See Instructions) HC, IN

     

    2 Represents 6,333,239 American Depositary Shares, each of which represents 5 Ordinary Shares of the Issuer.

     3 
    CUSIP No. 03217L106

     

    1.Names of Reporting Persons.

    Timothy P. Lynch

     

    2.Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) ______

    (b) X

     

    3. SEC Use Only

     

    4.Citizenship or Place of Organization U.S.A.

     

    Number of

    Shares

    Beneficially

    Owned by

    Each Reporting

    Person With:

    5. Sole Voting Power 31,666,1952

     

    6. Shared Voting Power 0

     

    7. Sole Dispositive Power 31,666,1952
    8. Shared Dispositive Power 0

     

    9.Aggregate Amount Beneficially Owned by Each Reporting Person 31,666,1952

     

     

    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See
    Instructions) ______

     

    11.Percent of Class Represented by Amount in Row (9) 9.9%

     

    12.Type of Reporting Person (See Instructions) HC, IN

     

    2 Represents 6,333,239 American Depositary Shares, each of which represents 5 Ordinary Shares of the Issuer.

     4 
    CUSIP No. 03217L106

     

    Item 1.

     

    (a)Name of Issuer

    Amryt Pharma plc

     

    (b)Address of Issuer’s Principal Executive Offices

    Dept 920a 196 High Road, Wood Green, London, United Kingdom, N22 8HH

     

     

    Item 2.

     

    (a)The names of the persons filing this statement are:

    Stonepine Capital Management, LLC, a California limited liability company (the “General Partner”)

     

    Stonepine Capital, L.P., a Delaware limited partnership (the “Partnership”)

     

    Jon M. Plexico

     

    Timothy P. Lynch (collectively, the “Filers”)

     

    The General Partner is the general partner and investment adviser of investment funds, including the Partnership. Mr. Plexico and Mr. Lynch are the control persons of the General Partner. The Filers are filing this Schedule 13G jointly, but not as members of a group, and each disclaims membership in a group. Each Filer also disclaims beneficial ownership of the Stock except to the extent of that person’s pecuniary interest therein. In addition, the filing of this Schedule 13G on behalf of the Partnership should not be construed as an admission that it is, and it disclaims that it is, a beneficial owner, as defined in Rule 13d-3 under the Act, of any of the Stock covered by this Schedule 13G.

     

    (b)The principal business office of the Filers is located at

     

    919 NW Bond Street, Suite 204

    Bend, OR 97703-2767

     

    (c)For citizenship of Filers, see Item 4 of the cover sheet for each Filer.

     

    (d)This statement relates to the Issuer’s Ordinary Shares, nominal value £0.06 per share (the “Stock”).

     

    (e)The CUSIP number of the Issuer is: 03217L106

     

     5 
    CUSIP No. 03217L106
    Item 3.If this statement is filed pursuant to rule 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a)[ ] Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

     

    (b)[ ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

     

    (c)[ ] Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).

     

    (d)[ ] Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).

     

    (e)[ X ] An investment adviser in accordance with section 240.13d-1(b)(1)(ii)(E). As to the General Partner.

     

    (f)[ ] An employee benefit plan or endowment fund in accordance with section 240.13d-1(b)(1)(ii)(F).

     

    (g)[ X ] A parent holding company or control person in accordance with 240.13d-1(b)(1)(ii)(G). As to Mr. Plexico and Mr. Lynch.

     

    (h)[ ] A savings association as defined in section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813).

     

    (i)[ ] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3).

     

    (j)[ ] A non-U.S. institution in accordance with §240.13d-1(b)(ii)(J).

     

    (k)[ ] Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

     

    If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution _______________________________________________________________.

     

    Item 4.Ownership.

     

    See Items 5-9 and 11 of the cover page for each Filer.

     

    The percentages reported in this Schedule 13G are based on 320,699,807 Ordinary Shares outstanding as of March 31, 2022, as reported in the Issuer’s Prospectus filed on May 20, 2022.

     

    Item 5.Ownership of Five Percent or Less of a Class

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ].

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

     

    The Partnership holds the Stock for the benefit of its investors and has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Stock.

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

     

    Not applicable.

     

    Item 8.Identification and Classification of Members of the Group.

     

    Not applicable.

     

    Item 9.Notice of Dissolution of Group

     

    Not applicable.


    Item 10.
    Material to Be Filed as Exhibits

    Agreement Regarding Joint Filing of Statement on Schedule 13D or 13G.

    Item 11.Certification of the General Partner, Mr. Plexico and Mr. Lynch

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

    Certification of the Partnership

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     6 
    CUSIP No. 03217L106

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: February 13, 2023

     

     

    STONEPINE CAPITAL MANAGEMENT, LLC


    By: /s/ Timothy P. Lynch _

    Timothy P. Lynch
    Managing Member

     

     

    STONEPINE CAPITAL, L.P.

    By: Stonepine Capital Management, LLC,
    General Partner

    By: /s/ Timothy P. Lynch

    Timothy P. Lynch
    Managing Member

     

     

     

    /s/ Jon M. Plexico

    Jon M. Plexico

     

     

     

    /s/ Timothy P. Lynch

    Timothy P. Lynch

     

     7 
    CUSIP No. 03217L106

    EXHIBIT A

     

    AGREEMENT REGARDING JOINT FILING

    OF STATEMENT ON SCHEDULE 13D OR 13G

     

    The undersigned agree to file jointly with the Securities and Exchange Commission (the “SEC”) any and all statements on Schedule 13D or Schedule 13G or Forms 3, 4 or 5(and any amendments or supplements thereto) required under section 13(d) and 16(a) of the Securities Exchange Act of 1934, as amended, in connection with purchases by the undersigned of the securities of any issuer. For that purpose, the undersigned hereby constitute and appoint Stonepine Capital Management, LLC, a California limited liability company, as their true and lawful agent and attorney-in-fact, with full power and authority for and on behalf of the undersigned to prepare or cause to be prepared, sign, file with the SEC and furnish to any other person all certificates, instruments, agreements and documents necessary to comply with section 13(d) and section 16(a) of the Securities Exchange Act of 1934, as amended, in connection with said purchases, and to do and perform every act necessary and proper to be done incident to the exercise of the foregoing power, as fully as the undersigned might or could do if personally present.

     

    Dated: May 15, 2017

     

     

    STONEPINE CAPITAL MANAGEMENT, LLC


    By: /s/ Timothy P. Lynch
    Managing Member

     

     

    STONEPINE CAPITAL, L.P.

    By: Stonepine Capital Management, LLC,
    General Partner

    By: /s/ Timothy P. Lynch
    Managing Member

     

     
    /s/ Jon M. Plexico
     

     


    /s/ Timothy P. Lynch

     

     

     

    Get the next $AMYT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AMYT

    DatePrice TargetRatingAnalyst
    9/6/2022$19.00Buy
    Canaccord Genuity
    3/10/2022$20.00 → $18.00Buy
    HC Wainwright & Co.
    3/10/2022$9.00 → $10.00Outperform
    SVB Leerink
    11/23/2021$23.00 → $19.00Outperform
    SVB Leerink
    10/4/2021$45.00Buy
    JonesTrading
    8/19/2021$22.00Outperform
    SVB Leerink
    8/19/2021$22.00Outperform
    Cowen
    7/27/2021$29.00Buy
    H.C. Wainwright
    More analyst ratings

    $AMYT
    Financials

    Live finance-specific insights

    See more
    • Amryt Reports Q3 2022 Financial and Operational Results

      Amryt Reports Q3 2022 Financial and Operational Results 8.2% YoY revenue growth in Q3 to $61.1M - 12.5% on a constant currency basis 11th consecutive quarter of positive EBITDA generation; $12.5M in Q3 2022 Operating cash flows of $14.3M for Q3 2022 Cash of $83.4M at September 30, 2022 Mycapssa® revenues increased 26.9% QoQ to $5.7M and 292.8% YoY CHMP positive opinion for Mycapssa® for the treatment of acromegaly in the EU Pathway agreed with the FDA to initiate a Phase 3 study for NET - expected in Q1 2023 Filsuvez® European launch progressing well Significant metreleptin LATAM $8.3M tender won - revenue expected to be recognized in Q4 Reaffirming FY 2022 revenue guidance to $26

      11/3/22 7:00:00 AM ET
      $AMYT
      $CHMA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Major Pharmaceuticals
    • Amryt to Report Q3 2022 Results on November 3, 2022

      Amryt to Report Q3 2022 Results on November 3, 2022 DUBLIN, Ireland, and Boston MA, October 19, 2022, Amryt (NASDAQ:AMYT) a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for rare diseases, today announces that its unaudited financial results for the third quarter 2022 will be released on Thursday, November 3, 2022 at 0700 ET/1100 GMT. Amryt will host a conference call and webcast for analysts and investors on November 3, 2022 at 0830 ET/1230 GMT. Webcast Player URL: https://edge.media-server.com/mmc/p/6nxxorrj Telephone Dial in details: Standard International Number + 39 (0) 02 802 0911 United States +1

      10/19/22 7:00:00 AM ET
      $AMYT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amryt Reports Record Q2 2022 Results

      Amryt Reports Record Q2 2022 Results 9.2% YoY revenue growth in Q2 to $68.5M 35.3% YoY revenue growth in Q2 excluding impact of a sporadic LATAM order in Q2 2021 7.8% growth in metreleptin revenues YoY to $46.4M in Q2 49.9% growth in metreleptin revenues in Q2 excluding impact of a sporadic LATAM order in Q2 2021 10th consecutive quarter of positive EBITDA generation Cash of $90.7M at June 30, 2022 Filsuvez® approved in the EU for the treatment of dystrophic and junctional EB Amryt now has four growing commercial products treating rare diseases Reaffirming FY 2022 revenue guidance to $260M - $270M, representing 17-21% YoY growth Stock repurchase program underway

      8/4/22 7:00:00 AM ET
      $AMYT
      $CHMA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Major Pharmaceuticals

    $AMYT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $AMYT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $AMYT
    Leadership Updates

    Live Leadership Updates

    See more

    $AMYT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Canaccord Genuity resumed coverage on Amryt Pharma plc with a new price target

      Canaccord Genuity resumed coverage of Amryt Pharma plc with a rating of Buy and set a new price target of $19.00

      9/6/22 8:49:27 AM ET
      $AMYT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. reiterated coverage on Amryt Pharma with a new price target

      HC Wainwright & Co. reiterated coverage of Amryt Pharma with a rating of Buy and set a new price target of $18.00 from $20.00 previously

      3/10/22 6:17:28 AM ET
      $AMYT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SVB Leerink reiterated coverage on Amryt Pharma with a new price target

      SVB Leerink reiterated coverage of Amryt Pharma with a rating of Outperform and set a new price target of $10.00 from $9.00 previously

      3/10/22 4:40:51 AM ET
      $AMYT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Amryt Pharma plc (Amendment)

      SC 13G/A - Amryt Pharma plc (0001783010) (Subject)

      4/18/23 4:15:50 PM ET
      $AMYT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Amryt Pharma plc (Amendment)

      SC 13G/A - Amryt Pharma plc (0001783010) (Subject)

      2/13/23 10:24:07 AM ET
      $AMYT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Amryt Pharma plc (Amendment)

      SC 13G/A - Amryt Pharma plc (0001783010) (Subject)

      2/10/23 4:00:19 PM ET
      $AMYT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amryt Announces Appointment of Dr Tracy Cunningham as Chief Medical Officer

      Amryt Announces Appointment of Dr Tracy Cunningham as Chief Medical Officer DUBLIN, Ireland, and Boston MA, June 27, 2022, Amryt (NASDAQ:AMYT), a global, commercial-stage biopharmaceutical company focussed on acquiring, developing and commercializing novel treatments for rare diseases, is pleased to announce the appointment of Dr Tracy Cunningham as Chief Medical officer (CMO) with immediate effect. Dr Cunningham joined Amryt in April 2020 as VP, Head of Development with responsibility for pre-clinical and clinical development of the Amryt portfolio. Prior to this, she held senior regional and global leadership roles in AstraZeneca, Novartis and GlaxoSmithKine. She is a graduate of the Roya

      6/27/22 7:00:00 AM ET
      $AMYT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amryt Announces the Appointment of Sheila Frame as President Americas

      DUBLIN, Ireland, and Boston MA, April 6, 2021, Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for rare diseases, is pleased to announce the appointment of Sheila Frame as President Americas. Sheila will lead all aspects of product commercialization for Amryt in the Americas.  Sheila has held senior leadership roles across several specialty areas with Novartis, Bristol-Myers Squibb, UCB, and AstraZeneca and has worked and lived in North America and in Europe.  Sheila holds an MBA from Concordia University. Dr Joe Wiley, CEO of Amryt Pharma, commented: “Sheila is a very experienced

      4/6/21 2:00:00 AM ET
      $AMYT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chiesi Farmaceutici S.p.A. Completes Acquisition of Amryt Pharma Plc

      ●  Acquisition positions Chiesi to expand patient access to approved treatments and advance efforts to develop new treatments for people living with rare diseases. PARMA, Italy, DUBLIN and BOSTON, MA, April 12, 2023 /PRNewswire/ -- Chiesi Farmaceutici S.p.A. ("Chiesi"), an international, research-focused biopharmaceuticals and healthcare group, today announced the completion of the acquisition of Amryt Pharma Plc ("Amryt") (NASDAQ:AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing, and commercializing novel treatments for rare diseases. "We are excited to add the Amryt family to our company in this acquisition that demonstrates our commitment to ra

      4/12/23 7:58:00 AM ET
      $AMYT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chiesi Farmaceutici S.p.A. Completes Acquisition of Amryt Pharma Plc

      Chiesi Farmaceutici S.p.A. Completes Acquisition of Amryt Pharma Plc Acquisition positions Chiesi to expand patient access to approved treatments and advance efforts to develop new treatments for people living with rare diseases. Parma Italy, Dublin Ireland and Boston MA, April 12, 2023 – Chiesi Farmaceutici S.p.A. ("Chiesi"), an international, research-focused biopharmaceuticals and healthcare group, today announced the completion of the acquisition of Amryt Pharma Plc ("Amryt") (NASDAQ:AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing, and commercializing novel treatments for rare diseases. "We are excited to add the Amryt family to our comp

      4/12/23 7:00:00 AM ET
      $AMYT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • High Court of Justice of England and Wales Sanctions Scheme of Arrangement

      High Court of Justice of England and Wales Sanctions Scheme of Arrangement Acquisition of Amryt Pharma by Chiesi Farmaceutici Expected to Close Mid-April 2023 Dublin, Ireland, April 3, 2023 Amryt Pharma Plc ("Amryt") (NASDAQ:AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing, and commercializing novel treatments for rare diseases, is pleased to announce that the High Court of Justice of England and Wales (the "Court") has sanctioned the scheme of arrangement providing for the proposed acquisition (the "Transaction") of Amryt by Chiesi Farmaceutici S.p.A. ("Chiesi") at a hearing held on March 31, 2023. The parties expect the closing of the Transa

      4/3/23 7:00:00 AM ET
      $AMYT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AMYT
    SEC Filings

    See more
    • SEC Form EFFECT filed by Amryt Pharma plc

      EFFECT - Amryt Pharma plc (0001783010) (Filer)

      4/24/23 12:15:24 AM ET
      $AMYT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 15F-12B filed by Amryt Pharma plc

      15F-12B - Amryt Pharma plc (0001783010) (Filer)

      4/24/23 6:00:57 AM ET
      $AMYT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Amryt Pharma plc

      EFFECT - Amryt Pharma plc (0001783010) (Filer)

      4/24/23 12:15:20 AM ET
      $AMYT
      Biotechnology: Pharmaceutical Preparations
      Health Care